
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
2'-Fucosyllactose (2'-FL) Human Milk Oligosaccharide is a prebiotic compound that selectively feeds beneficial gut bacteria, particularly Bifidobacteria. It works by resisting digestion in the small intestine and fermenting in the colon to produce short-chain fatty acids.

Reported Benefits (Provisional)
Origin & History

Human Milk Oligosaccharides are complex sugars found in human breast milk. 2'-FL HMO is produced through microbial fermentation for use in supplements and infant formulas.
Research Narrative (Provisional)
Research, including randomized controlled trials, indicates that 2'-FL HMO supports gut health and immune function in infants. Studies also suggest benefits for adults.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
{"macronutrients": {"carbohydrates": "Predominantly composed of lactose-derived oligosaccharides", "fiber": "Functions as a prebiotic fiber, though not quantified in traditional fiber measurements"}, "micronutrients": {"minerals": {"calcium": "Trace amounts, not a significant source", "phosphorus": "Trace amounts, not a significant source"}, "vitamins": {"vitamin_c": "Not present", "vitamin_d": "Not present"}}, "bioactive_compounds": {"2'-fucosyllactose (2'-FL)": "Approximately 2-3 grams per liter in human milk", "lactose": "Present as a base component of oligosaccharides"}, "bioavailability_notes": "2'-FL HMO is highly bioavailable, specifically targeting beneficial gut bacteria like Bifidobacteria. It is resistant to digestion in the upper gastrointestinal tract, reaching the colon intact to exert its prebiotic effects."}
Reported Mechanism (Provisional)
2'-FL HMO binds to pathogenic bacteria in the gut, preventing their adhesion to intestinal epithelial cells through competitive inhibition. The compound selectively stimulates Bifidobacterium and Lactobacillus growth via fermentation, producing butyrate and acetate that strengthen intestinal barrier function. It also modulates immune responses by activating dendritic cells and promoting anti-inflammatory cytokine production.
Clinical Narrative (Provisional)
Human studies with 2'-FL HMO supplementation (0.2-2g daily) show significant increases in Bifidobacteria populations within 2-4 weeks. A randomized controlled trial with 175 healthy adults demonstrated 30% reduction in upper respiratory tract infections over 12 weeks. Infant studies indicate improved stool consistency and reduced crying time, though long-term safety data in adults remains limited to 24-week studies.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







